We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Research Article

Investigation of ethyl cellulose microsponge gel for topical delivery of eberconazole nitrate for fungal therapy

    Chellampillai Bothiraja

    *Author for correspondence:

    E-mail Address: pounbothi@yahoo.com

    Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune 411038, Maharashtra, India

    Search for more papers by this author

    ,
    Amol D Gholap

    Department of Pharmaceutics, Sharadchandra Pawar College of Pharmacy, University of Pune, Otur, Pune 412409, Maharashtra, India

    Search for more papers by this author

    ,
    Karimunnisa S Shaikh

    Department of Pharmaceutics, Modern College of Pharmacy, Nigdi, Pune 411044, Maharashtra, India

    Search for more papers by this author

    &
    Atmaram P Pawar

    Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune 411038, Maharashtra, India

    Search for more papers by this author

    Published Online:7 Oct 2014https://doi.org/10.4155/tde.14.43

    Abstract

    Background: The aim of the study was to investigate ethyl cellulose microsponges as topical carriers for the controlled release and cutaneous drug deposition of eberconazole nitrate (EB). Materials & method: EB microsponges were prepared using the quasiemulsion solvent diffusion method. The effect of formulation variables (drug:polymer ratio, internal phase volume and amount of emulsifier) and process variables (stirring time and stirring speed) on the physical characteristics of microsponges were investigated. The optimized microsponges were dispersed into a hydrogel and evaluated. Results & discussion: Spherical and porous EB microsponge particles were obtained. The optimized microsponges possessed particle size, drug content and entrapment efficiency of 24.5 µm, 43.31% and 91.44%, respectively. Microsponge-loaded gels demonstrated controlled release, nonirritancy to rat skin and antifungal activity. An in vivo skin deposition study demonstrated fourfold higher retention in the stratum corneum layer as compared with commercial cream. Conclusion: Developed ethyl cellulose microsponges could be potential pharmaceutical topical carriers of EB in antifungal therapy.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest.

    References

    • 1 Sabyasachi M, Santanu K, Somasree R et al. Development and evaluation of xanthan gum-facilitated ethyl cellulose microsponges for controlled percutaneous delivery of diclofenac sodium. Acta Pharmaceut. 61(3), 257–270 (2011).
      MedlineGoogle Scholar
    • 2 Amrutiya N, Bajaj A, Madan M. Development of microsponges for topical delivery of mupirocin. AAPS PharmSciTech 10(2), 402–409 (2009).
      Medline CASGoogle Scholar
    • 3 Herwadkar A, Banga AK. An update on the application of physical technologies to enhance intradermal and transdermal drug delivery. Ther. Deliv. 3(3), 339–355 (2012).
      CASGoogle Scholar
    • 4 Prasad R, Koul V. Transdermal delivery of methotrexate: past, present and future prospects. Ther. Deliv. 3(3), 315–325 (2012).
      CASGoogle Scholar
    • 5 Gomez C, Benito M, Teijon JM et al. Novel methods and devices to enhance transdermal drug delivery: the importance of laser radiation in transdermal drug delivery. Ther. Deliv. 3(3), 373–388 (2012)
      CASGoogle Scholar
    • 6 Siddoju S, Sachdeva V, Friden PM et al. Evaluation of acyclovir cream and gel formulations for transdermal iontophoretic delivery. Ther. Deliv. 3(3), 327–338 (2012).
      CASGoogle Scholar
    • 7 Jansen J, Maibach HI. Encapsulation to deliver topical actives. In: Handbook of Cosmetic Science and Technology. Barel AO, Paye M, Maibach HI (Eds). CRC Press, FL, USA, 125–144 (2006).
      Google Scholar
    • 8 Chadawar V, Shaji J. Microsponge delivery. Curr. Drug Deliv. 4(2), 123–129 (2007).
      Medline CASGoogle Scholar
    • 9 Nokhodchi A, Jelvehgari M, Siahi MR et al. Factors affecting the morphology of benzoyl peroxide microsponges. Micron 38(8), 834–840 (2007).•• Reveals the mechanism of microsponge formation.
      Medline CASGoogle Scholar
    • 10 Vikas J, Deepika J, Ranjit S. Factors effecting the morphology of eudragit S-100 based microsponges bearing dicyclomine for colonic delivery. J. Pharm. Sci. 100(4), 1545–1552 (2011).
      MedlineGoogle Scholar
    • 11 Jorizzo J, Grossman R, Nighland M. Tretinoin microsphere gel in younger acne patients. J. Drugs Dermatol. 7(8), 9–13 (2008).• Reveals the advantages of microsponges over other topical carriers.
      Google Scholar
    • 12 Menter A, Vamvakias G, Jorizzo J. One-week treatment with once-daily fluorouracilcream 0.5% in participants with actinic keratoses. Cutis 81(6), 509–516 (2008).
      MedlineGoogle Scholar
    • 13 Repiso MT, Lopez S, Rodriguez C et al. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int. J. Dermatol. 45(5), 600–604 (2006).
      MedlineGoogle Scholar
    • 14 Zalacain A, Obrador C, Martinez JP et al. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain. Med. Mycol. 49(5), 495–499 (2011).
      Medline CASGoogle Scholar
    • 15 Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am. J. Clin. Dermatol. 3(2), 71–81 (2002).
      MedlineGoogle Scholar
    • 16 Moodahadu-Bangera LS, Martis J, Mittal R et al. Eberconazole – pharmacological andclinical review. Indian J. Dermatol. Venereol. Leprol. 78(2), 217–222 (2012).
      MedlineGoogle Scholar
    • 17 Barbanoj MJ, Antonijoan R, García-Gea C et al. Eberconazole cream: topical and general tolerability, sensitisation potential and systemic availability. Method Find. Exp. Clin. 27(4), 227–234 (2005).•• Presents the pharmaceutical problems associated with bioactive eberconazole nitrate.
      Medline CASGoogle Scholar
    • 18 Shaikh KS, Bothiraja C, Pawar AP. Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine nonionic surfactant vesicles of ciclopirox olamine. Drug Dev. Ind. Pharm. 36(8), 946–953 (2010).
      Medline CASGoogle Scholar
    • 19 Lademann J, Jacobi U, Surber C et al. The tape stripping procedure – evaluation of some critical parameters. Eur. J. Pharm. Biopharm. 72(2), 317–323 (2008). •• Suggests a protocol for an in vivo skin deposition study.
      MedlineGoogle Scholar
    • 20 Thomas J, Schloemer B. Primary skin irritation test in the rabbit of water jel burn dressing. http://www.waterjel.com/public/Skin irritation Test.pdf (Accessed 11 March 2006) • Presents a protocol for a skin irritation study for topical formulations.
      Google Scholar
    • 21 Maheshwari RGS, Tekade RK, Sharma PA et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm. J. 20(2), 161–170 (2012).
      MedlineGoogle Scholar
    • 22 Pawar AP, Shelake MR, Bothiraja C et al. Development of photostable gastro retentive formulation for nifedipine using low-density polypropylene microporous particles. J. Microencapsul. 29(5), 409–416 (2011).•• Presents the mechanism of drug release from microparticles.
      Google Scholar
    • 23 Hainey P, Huxham IM, Rowatt B et al. Synthesis and ultrastructural studies of styrene–divinylbenzene polyhip polymers. Macromolecules 24(1), 117–121 (1991).
      CASGoogle Scholar
    • 24 Comoglu T, Gonul N, Baykara T. Preparation and in vitro evaluation of modified release ketoprofen microsponges. Il Farmaco 58(2), 101–106 (2003).• Presents the method of preparation of microsponges.
      Medline CASGoogle Scholar
    • 25 Orlu M, Cevher E, Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int. J. Pharm. 318(1–2), 103–117 (2006).
      Medline CASGoogle Scholar
    • 26 Rajkumar S, Akanksha T. Carbohydrate polymers: applications and recent advances in delivering drugs to the colon. Carbohyd. Polym. 88(2), 399–416 (2012).
      Google Scholar
    • 27 Reddy L, Murthy RSR. Study of influence of polymerization factors on formation of poly(butyl cyanoacrylate) nanoparticles and in-vitro drug release kinetics. Arch. Pharm. 45(3), 211–234 (2004).
      Google Scholar
    • 28 Bothiraja C, Kapare HS, Pawar AP et al. Development of plumbagin-loaded phospholipid-Tween® 80 mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing, Ther. Deliv. 4(10), 1247–1259 (2013). •• Presents the role of surfactants in the therapeutic delivery system.
      CASGoogle Scholar
    • 29 Santanu K, Jinu I, Animesh G. Interpenetrating polymer network of locust bean gum–poly (vinyl alcohol) for controlled release drug delivery. Carbohyd. Polym. 94(1), 456–467 (2013).
      MedlineGoogle Scholar
    • 30 Pagar KP, Vavia PR. Poly[LA-(Glc-Leu)] copolymer as a carrier for ocular delivery of ciprofloxacin: formulation, characterization and in vivo biocompatibility study. Ther. Deliv. 4(5), 553–565 (2013).
      CASGoogle Scholar
    • 31 Raju A, Muthu MS, Feng SS. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin. Drug Deliv. 10(6), 747–760 (2013).
      Medline CASGoogle Scholar
    • 32 Jelvehgari M, Siahi-Shadbad MR, Azarmi S et al. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int. J. Pharm. 308(1–2), 124–132 (2006).
      Medline CASGoogle Scholar
    • 33 Alvarez-Roman R, Naik A, Kalia YN et al. Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res. 21(10), 1818–1824 (2004).
      Medline CASGoogle Scholar